Ymir Genomics, MUSC to Search for Bladder Cancer Biomarkers | GenomeWeb

NEW YORK (GenomeWeb) – Ymir Genomics today announced a biomarker discovery agreement with the Medical University of South Carolina targeting bladder cancer. 

The firm aims to develop a diagnostic kit leveraging Ymir's urinary extracellular vesicle/RNA isolation technology and the expertise of the university's proteomics center. Ymir will isolate extracellular vesicles and RNA and analyze miRNA profiles of urine collected from patients with bladder cancer, as well as controls. MUSC will take the isolated vesicle preps and profile them based on proteins, glycans, and lipids. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Dec
08
Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.